Pharmaleads Presents New Data Showing DENKIs, a New Class of Painkillers, to be Devoid of Abuse Potential and Opiate Side-Effects

Clinical and preclinical data demonstrating efficacy, safety and tolerability presented at the Annual International Conference on Opioids in Boston

Paris, France, 11 June  2018 – Pharmaleads, an emerging pharmaceutical company developing innovative non-opiate products for the management of acute and chronic severe pain, today announced new clinical and preclinical data showing the efficacy, safety and tolerability of its novel Dual ENKephalinase Inhibitors (DENKIs), PL265 and PL37. These data were presented by Pharmaleads and its collaborators from the University Paris Descartes, France, the Universitat Pompeu Fabra, Barcelona, Spain, and the University of Michigan, US at the International Conference on Opioids (ICOO2018) in Boston today.

“The data presented shows that PL265 and PL37 are devoid of any abuse potential  even at high doses and after repeated administration while providing similar levels of pain relief to opiates, but without their side-effects,” said Michel Wurm, VP Medical Affairs at Pharmaleads. “Our DENKIs have the potential to offer a solution to the opioid crisis by providing safe and non-addictive relief to patients suffering from multiple types of severe pain.”

Download Full Version

Press releases - Latest posts

Discover our publications